{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977427",
  "id": "02977427",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250806",
  "time": "0938",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml86xg3cbxlk.pdf",
  "summary": "- **Positive Phase I Clinical Trial Results**:  \n  - No dose-limiting safety signals observed; Xolatryp\u2122 well tolerated in all six cohorts.  \n  - Topline results expected in **September 2025 quarter**.  \n  - Phase IIa trial in acute myocardial infarction (STEMI) patients planned for **early 2026**.  \n\n- **Preclinical Efficacy**:  \n  - Xolatryp demonstrated **42% cardioprotection** (3-hour dosing) and reduced arrhythmias in coronary heart disease models.  \n  - Statistically significant neuroprotective effects in **traumatic brain injury** and **stroke models**.  \n\nNo capital markets or liquidity-impacting actions announced. Focus remains on clinical milestones.",
  "usage": {
    "prompt_tokens": 2057,
    "completion_tokens": 146,
    "total_tokens": 2203,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T23:57:58.529498"
}